X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ramucirumab (315) 315
index medicus (191) 191
oncology (173) 173
humans (151) 151
double-blind (133) 133
chemotherapy (118) 118
angiogenesis (115) 115
bevacizumab (106) 106
gastric cancer (97) 97
cancer (93) 93
endothelial growth-factor (85) 85
1st-line therapy (73) 73
vascular endothelial growth factor (71) 71
open-label (64) 64
antibodies, monoclonal - therapeutic use (63) 63
paclitaxel (57) 57
female (56) 56
stomach cancer (56) 56
care and treatment (53) 53
metastasis (53) 53
cancer therapies (52) 52
pharmacology & pharmacy (51) 51
male (48) 48
adenocarcinoma (45) 45
aged (45) 45
antineoplastic combined chemotherapy protocols - therapeutic use (45) 45
middle aged (43) 43
treatment outcome (43) 43
antineoplastic agents - therapeutic use (42) 42
stomach neoplasms - drug therapy (42) 42
clinical trials (41) 41
docetaxel (41) 41
angiogenesis inhibitors - therapeutic use (40) 40
antibodies, monoclonal - administration & dosage (40) 40
multicenter (38) 38
placebo (38) 38
vegf (38) 38
adult (36) 36
medicine & public health (36) 36
colorectal cancer (35) 35
patients (35) 35
review (35) 35
survival (35) 35
animals (33) 33
antibodies, monoclonal - adverse effects (33) 33
tumors (33) 33
disease-free survival (32) 32
regorafenib (32) 32
monoclonal antibodies (31) 31
phase-iii trial (31) 31
supportive care (30) 30
combination (29) 29
drug therapy (29) 29
gastroenterology & hepatology (29) 29
randomized phase-iii (29) 29
therapy (29) 29
immunotherapy (28) 28
stomach neoplasms - pathology (28) 28
cancer research (27) 27
neovascularization, pathologic - drug therapy (27) 27
nivolumab (26) 26
sorafenib (26) 26
studies (26) 26
advanced gastric cancer (25) 25
oxaliplatin (25) 25
research (25) 25
antineoplastic combined chemotherapy protocols - adverse effects (24) 24
lung neoplasms - drug therapy (24) 24
targeted therapy (24) 24
trial (24) 24
1st-line treatment (23) 23
2nd-line treatment (23) 23
carcinoma, non-small-cell lung - drug therapy (23) 23
pembrolizumab (23) 23
antineoplastic agents - adverse effects (22) 22
disease progression (22) 22
molecular targeted therapy (22) 22
neoplasms. tumors. oncology. including cancer and carcinogens (22) 22
biomarkers (21) 21
colorectal neoplasms - drug therapy (21) 21
irinotecan (21) 21
medical prognosis (21) 21
analysis (20) 20
antineoplastic agents - pharmacology (20) 20
cabozantinib (20) 20
fluorouracil (20) 20
medical research (20) 20
neoplasms - drug therapy (20) 20
trastuzumab (20) 20
adenocarcinoma - drug therapy (19) 19
antibodies, monoclonal - pharmacology (19) 19
hematology, oncology and palliative medicine (19) 19
lung cancer (19) 19
metastases (19) 19
vascular endothelial growth factor receptor-2 - antagonists & inhibitors (19) 19
aflibercept (18) 18
biotechnology & applied microbiology (18) 18
cisplatin (18) 18
gastroesophageal junction (18) 18
hepatocellular carcinoma (18) 18
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (336) 336
Russian (7) 7
French (2) 2
Hungarian (2) 2
Spanish (2) 2
German (1) 1
Japanese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Japanese Journal of Cancer and Chemotherapy, ISSN 0385-0684, 10/2018, Volume 45, Issue 10, pp. 1549 - 1551
Journal Article
Japanese Journal of Cancer and Chemotherapy, ISSN 0385-0684, 11/2017, Volume 44, Issue 11, pp. 1021 - 1023
Journal Article
Oncotarget, ISSN 1949-2553, 04/2018, Volume 9, Issue 32, pp. 22332 - 22339
Hypertension (HTN) is frequently associated with the use of angiogenesis inhibitors targeting the vascular endothelial growth factor pathway, such as... 
Hypertension | Gastric cancer | Ramucirumab
Journal Article
Internal Medicine, ISSN 0918-2918, 2018
Extrapulmonary neuroendocrine carcinoma (NEC) is a rare disease, and there is no standard chemotherapy. A 73-year-old man was diagnosed with advanced gastric... 
VEGFR2 | paclitaxel | ramucirumab | neuroendocrine carcinoma | chemotherapy
Journal Article
Oncotarget, ISSN 1949-2553, 2018, Volume 9, Issue 20, pp. 15219 - 15227
Anti-vascular endothelial growth factor (VEGF) therapeutics such as bevacizumab, which are widely used in cancer treatment, commonly leads to hypertension.... 
Hypertension | Ramucirumab | Toxicity | Gastric cancer | Paclitaxel
Journal Article
Oncotarget, ISSN 1949-2553, 06/2018, Volume 9, Issue 47, pp. 28292 - 28293
Journal Article
Critical Reviews in Oncology / Hematology, ISSN 1040-8428, 11/2019, Volume 143, pp. 27 - 45
Although paclitaxel plus ramucirumab has been recommended as the preferred second-line strategy, other regimens also display potentially comparable efficacies.... 
Refractory | Apatinib | Second-line systemic therapy | Paclitaxel plus ramucirumab | Nivolumab
Journal Article
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, ISSN 1130-0108, 2019, Volume 111, Issue 10, pp. 727 - 730
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 859 - 870
Journal Article
Медицинский совет, ISSN 2079-701X, 06/2019, Issue 10, pp. 136 - 140
The low efficacy of cytostatic therapy in mGC led to an active study of the role of molecular targets in the carcinogenesis of GC. Ramucirumab is the only... 
gastric cancer | ramucirumab | angiogenesis | second line treatment
Journal Article
Revue des Maladies Respiratoires Actualites, ISSN 1877-1203, 05/2015, Volume 7, Issue 2, pp. 138 - 145
Screening, targeted therapies, mutations, maintenance. . . Thoracic oncology is progressing quickly. This trend was confirmed in 2014, with important... 
Crizotinib | Ramucirumab | Ceritinib | Nintedani
Journal Article
Recenti Progressi in Medicina, ISSN 0034-1193, 04/2016, Volume 107, Issue 4, pp. 193 - 198
Journal Article
Journal Article
by Lu, S and Chang, JH and Liu, XQ and Shi, JH and Lu, Y and Li, W and Yang, JJ and Zhou, JY and Wang, J and An, TT and Yang, L and Liu, Z and Zhou, XD and Chen, M and Hua, Y and Su, WG
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 04/2018, Volume 36, Issue 12, pp. 1207 - 1207
PurposePatients with advanced nonsmall-cell lung cancer (NSCLC) who fail two lines of chemotherapy have unmet medical needs. The kinase inhibitor fruquintinib... 
RAMUCIRUMAB | CONTROLLED-TRIAL | PEMBROLIZUMAB | ONCOLOGY | BEVACIZUMAB | ADENOCARCINOMA | TYROSINE KINASES | OPEN-LABEL | 1ST-LINE THERAPY | DOCETAXEL | METASTATIC COLORECTAL-CANCER
Journal Article
Expert Opinion on Biological Therapy, ISSN 1471-2598, 11/2019, Volume 19, Issue 11, pp. 1135 - 1141
Introduction: Gastric cancer remains one of the most lethal malignancy, accounting for an estimated 783,000 deaths worldwide in 2018. Although there are... 
targeted therapy | VEGFR-2 inhibitors | Ramucirumab | gastric cancer | gastroesophageal adenocarcinoma
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 12/2017, Volume 39, Issue 12, pp. 2380 - 2388
The combination of paclitaxel + ramucirumab is a standard second-line treatment in patients with advanced gastric cancer. This therapy has been associated with... 
cost-effectiveness | paclitaxel | Markov model | gastric cancer | ramucirumab | Stomach cancer
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.